Regulus Therapeutics (RGLS) shares were down 21% in recent trading Wednesday even after the company said that a portion of subjects benefited from farabursen in an early-stage study.
Interim results from the fourth cohort of subjects enrolled in the company's phase 1b study of farabursen found that patients with autosomal dominant polycystic kidney disease, or ADPKD, responded to the treatment.
The interim data was based on the first 14 subjects of the cohort who also saw a "notable reduction" in height-adjusted total kidney volume growth rate, the company said.
Additionally, all 26 subjects in the cohort demonstrated that farabursen was well tolerated, according to Regulus.
Meanwhile, the company said it had successfully concluded a meeting with the US Food and Drug Administration in December, reaching an agreement on the design of a phase 3 trial of farabursen.
Price: 0.92, Change: -0.25, Percent Change: -21.03
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。